𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Milestones in Parkinson's disease—Clinical and pathologic features

✍ Scribed by Glenda Halliday; Andrew Lees; Matthew Stern

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
350 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The identification of the widespread deposition of fibrillized α‐synuclein in Lewy bodies and Lewy neurites in the brains of patients with Parkinson's disease in 1997 has had a profound impact on how the disease is now conceptualized. The previous focus on the loss of the dopaminergic nigrostriatal system, the concept of subcortical dementia, and the idea that Parkinson's disease was dominated by motor impairment have all given way to research assessing more diverse brain regions, clinical symptoms, and phenotypes. It is now recognized that Parkinson's disease is more than just a loss of midbrain dopaminergic neurons in association with Lewy bodies. There are now several theories on how the disease develops and progresses currently being validated in a variety of studies, although many of these theories have yet to incorporate the phenotypic clinical and pathological changes associated with age. A particularly exciting new area of research involves the cell‐to‐cell transmission of pathogenic proteins. The recent consensus definition of Parkinson's disease dementia will allow its pathologic substrates to be determined. These advances have progressed to a stage where the preclinical stages of Parkinson's disease and its specific signs and symptoms are being predicted and tested clinically. Such strategies herald a future wave of preventive strategies for Parkinson's disease and its clinical symptoms. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

Milestones in Parkinson's disease therap
Milestones in Parkinson's disease therapeutics
✍ Olivier Rascol; Andres Lozano; Matthew Stern; Werner Poewe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. I

Parkinson's disease, proteins, and prion
Parkinson's disease, proteins, and prions: Milestones
✍ C. Warren Olanow; K. McNaught 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 494 KB 👁 1 views

## Abstract Parkinson's disease (PD) is characterized by protein accumulation in the form of Lewy bodies and neurites. It is thus reasonable to consider that alterations in protein handling in the form of increased production, impaired clearance, or both might be central to the etiopathogenesis of

Premotor Parkinson's disease: Clinical f
Premotor Parkinson's disease: Clinical features and detection strategies
✍ Randolph Stephenson; Andrew Siderowf; Matthew B. Stern 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract In many areas of medicine, the focus has shifted from treating existing disease to screening and prevention. The technology to screen for Parkinson's disease (PD) already exists. The current challenge is to define the appropriate use of predictive testing for PD. Imaging technologies cu

Prevalence and clinical features of hedo
Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease
✍ Francesca Romana Pezzella; Carlo Colosimo; Nicola Vanacore; Simone Di Rezze; Mel 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

## Abstract Hedonistic homeostatic dysregulation (HHD) is a neuropsychiatric disorder recently described in Parkinson's disease (PD), which is characterized by self‐medication and addiction to dopaminergic drugs. To understand the prevalence of this disorder, we screened 202 PD patients attending o